CN112424226B - 用于治疗重度哮喘的抗cd6抗体 - Google Patents

用于治疗重度哮喘的抗cd6抗体 Download PDF

Info

Publication number
CN112424226B
CN112424226B CN201980027155.5A CN201980027155A CN112424226B CN 112424226 B CN112424226 B CN 112424226B CN 201980027155 A CN201980027155 A CN 201980027155A CN 112424226 B CN112424226 B CN 112424226B
Authority
CN
China
Prior art keywords
asthma
antibody
cells
antigen
severe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980027155.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN112424226A (zh
Inventor
斯蒂芬·康纳利
切丽·吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Balance Biotechnology Co ltd
Original Assignee
Balance Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Balance Biotechnology Co ltd filed Critical Balance Biotechnology Co ltd
Publication of CN112424226A publication Critical patent/CN112424226A/zh
Application granted granted Critical
Publication of CN112424226B publication Critical patent/CN112424226B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980027155.5A 2018-02-27 2019-02-27 用于治疗重度哮喘的抗cd6抗体 Active CN112424226B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862636092P 2018-02-27 2018-02-27
US62/636,092 2018-02-27
PCT/US2019/019872 WO2019169015A1 (en) 2018-02-27 2019-02-27 Anti cd6 antibodies for treating severe asthma

Publications (2)

Publication Number Publication Date
CN112424226A CN112424226A (zh) 2021-02-26
CN112424226B true CN112424226B (zh) 2025-03-14

Family

ID=65724591

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980027155.5A Active CN112424226B (zh) 2018-02-27 2019-02-27 用于治疗重度哮喘的抗cd6抗体

Country Status (14)

Country Link
US (2) US20210380711A1 (https=)
EP (1) EP3759140A1 (https=)
JP (1) JP7572041B2 (https=)
KR (1) KR20200128415A (https=)
CN (1) CN112424226B (https=)
AU (1) AU2019228508A1 (https=)
BR (1) BR112020017445A2 (https=)
CA (1) CA3091920A1 (https=)
IL (1) IL276875A (https=)
MX (1) MX2020008916A (https=)
PH (1) PH12020551323A1 (https=)
SG (1) SG11202008149RA (https=)
WO (1) WO2019169015A1 (https=)
ZA (1) ZA202005320B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201001467A1 (ru) 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
CA2920368C (en) 2013-07-23 2023-03-21 Centro De Inmunologia Molecular Use of a cd6 binding partner and method based thereon
PL3529274T3 (pl) 2016-10-21 2024-09-09 Biocon Limited Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
AU2021392748A1 (en) * 2020-12-04 2023-06-29 Equillium, Inc. Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102559636A (zh) * 2011-12-30 2012-07-11 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
CA2282410A1 (en) 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
KR101482959B1 (ko) 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
EA201001467A1 (ru) 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
JP6296650B2 (ja) 2013-03-13 2018-03-20 国立大学法人 筑波大学 免疫疾患に対する医薬組成物
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
CA2992262A1 (en) 2015-07-15 2017-01-19 Kyowa Hakko Kirin Co., Ltd. Antibody which specifically binds to human crth2
WO2017218750A1 (en) * 2016-06-15 2017-12-21 The Cleveland Clinic Foundation Novel anti-cd6 antibodies for treating t-cell mediated conditions
JP7065085B2 (ja) * 2016-10-18 2022-05-11 バイオコン・リミテッド Ｃｄ６のリン酸化を低減させるためのイトリズマブの使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102559636A (zh) * 2011-12-30 2012-07-11 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"High IFN-γ and low SLPI mark severe asthma in mice and humans";Mahesh Raundhal et al.;《The Journal of Clinical Investigation》;20150831;第125卷(第8期);第3037-3050页 *
"Th17 cells: new players in asthma pathogenesis";L. Cosmi et al.;《Allergy》;20111231;第66卷;第989-998页 *
"The effect of activated leukocyte cell adhesion molecule on development of Th2 inflammation in a mouse model of allergic asthma";Mi Na Kim;《The Doctoral Dissertation》;20171231;第1-76页 *
"Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab";Patricia Hernández et al.;《Current Drug Targets》;20160229;第17卷;第665-676页 *

Also Published As

Publication number Publication date
PH12020551323A1 (en) 2021-04-26
JP2021515039A (ja) 2021-06-17
JP7572041B2 (ja) 2024-10-23
AU2019228508A1 (en) 2020-09-17
SG11202008149RA (en) 2020-09-29
US20210380711A1 (en) 2021-12-09
IL276875A (en) 2020-10-29
RU2020130563A3 (https=) 2022-04-01
US20250034272A1 (en) 2025-01-30
WO2019169015A1 (en) 2019-09-06
BR112020017445A2 (pt) 2021-01-26
CA3091920A1 (en) 2019-09-06
MX2020008916A (es) 2021-02-15
KR20200128415A (ko) 2020-11-12
RU2020130563A (ru) 2022-03-28
CN112424226A (zh) 2021-02-26
ZA202005320B (en) 2022-02-23
EP3759140A1 (en) 2021-01-06

Similar Documents

Publication Publication Date Title
JP7695298B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
AU2020277207B2 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
CN112424226B (zh) 用于治疗重度哮喘的抗cd6抗体
JP7194104B2 (ja) 抗ｔｌ１ａモノクローナル抗体の中和
JP6995844B2 (ja) アトピー性皮膚炎を治療するためのｉｌ－１３アンタゴニストの使用
IL240898A (en) Anti-c5a antibodies for manufacture of medicaments for treating complement-associated disorders
JP2022518399A (ja) Ｐｄ－１軸結合アンタゴニスト及びｒｎａワクチンを用いてがんを処置する方法
US20210000949A1 (en) Methods for treating or preventing asthma by administering an il-33 antagonist
CN102281898B (zh) Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用
RU2796586C2 (ru) Антитела к cd6 для лечения тяжелой астмы
KR20240049304A (ko) 융합 단백질을 함유하는 약학적 조성물
HK40042290A (en) Anti cd6 antibodies for treating severe asthma
US12409208B2 (en) Treating tissue fibrosis with interleukin 24
RU2801531C2 (ru) Способы лечения или предотвращения астмы посредством введения антагониста il-4r
KR20230123477A (ko) 급성 호흡곤란 증후군의 치료 또는 예방 방법
TWI739625B (zh) 投與il-4r拮抗劑以治療或預防氣喘之方法
WO2026086834A1 (zh) 抗ox40抗体在治疗皮炎疾病中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042290

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant